Low Dose Naltrexone – LDN

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome.

Evidence suggests that LDN may act as a novel anti-inflammatory agent in the central nervous system by modulating microglial activity. These effects may be unique to low dosages of naltrexone and appear to be entirely independent of naltrexone’s better-known activity on opioid receptors.

As a daily oral therapy, LDN is inexpensive and well-tolerated. 

LDN may be among the first glial cell modulators to treat chronic pain disorders.

https://ldnresearchtrust.org